



Fortis Healthcare (India) Limited
Escorts Heart Institute and Research Centre,
Okhla Road, New Delhi - 110 025 (India)
Tel : + 91-11-2682 5000, 2682 5001
Fax : + 91-11-4162 8435
E-mail : contactus@fortishealthcare.com
Website : www.fortishealthcare.com

THROUGH COURIER/FAX – 022-26598237, 26598238

FHL/SEC/S-2/AR/2011-12
April 19, 2011

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra – Kurla Complex,
Bandra (East),
Mumbai - 400051

Sub: Press Release


Dear Sirs,

Please note that Fortis' strategic stake in Super Religare Laboratories Ltd. to be based upon benchmark set by Private Equity player Avigo Capital Partners.

A copy of Press Release, being issued by the Company in this regard, is enclosed for your reference and records please.

Thanking you,

Yours faithfully,
for Fortis Healthcare (India) Limited



Ruchi Mahajan
Ruchi Mahajan
Company Secretary

Encl: As above

PRESS RELEASE

Fortis' strategic stake in Super Religare Laboratories Ltd to be based upon benchmark set by Private Equity player Avigo Capital Partners

New Delhi, April 19, 2011: Avigo Capital Partners has acquired 9.27% equity in Super Religare Laboratories Ltd (SRL) for Rs 100 crores. SRL is very pleased with this association on account of Avigo's understanding of the Healthcare space and at the prospect of future value creation. SRL is also very pleased at the expressions of interest by a large number of Private Equity Funds that were keen to associate with it.

The Board of Fortis Healthcare (India) Ltd in its meeting today approved to acquire SRL on the third party valuation, based on the Private Equity Fund Avigo. Fortis had received an in-principal approval from its Board of Directors last week, to acquire ~86% stake in Super Religare Laboratories Ltd (SRL): one of India's largest and leading diagnostic services companies, offering diagnostic testing (including Pathology and Radiology), preventive care testing and clinical research trial testing.

Fortis Healthcare (India) Ltd's acquisition of SRL stake is clearly beneficial to both entities, as it will enable the delivery of end-to-end healthcare services to patients. The acquisition of controlling interest in SRL will create room for many new synergies between Fortis and SRL. In making SRL an integral part of its delivery network, Fortis will become an integrated player including expertise in pathology and radiology. It is commonly acknowledged that over 70% of all clinical decisions depend on diagnostic outcomes. SRL has a huge retail presence outside of hospital premises and a large number of its customers are found to need hospital intervention. SRLs accredited national network of pathology and radiology labs, with high reporting standards and rapid turnout capability will positively impact patient health outcomes. Fortis' existing healthcare delivery infrastructure will certainly be enhanced by the clinical synergy that will result from this acquisition.

Speaking on the developments, **Mr. Shivinder Mohan Singh, Managing Director, Fortis Healthcare (India) Ltd** said, "We look forward to building upon the Diagnostics business and expanding our presence into new segments. Fortis is committed to providing an integrated healthcare platform and continually seeks ways to enable *Medical Inclusion* in India and offer *value-based medicine* to patients." According to **Dr Sanjeev K Chaudhry, CEO Super Religare Laboratories Ltd**, "We are glad to be associated with Fortis and Avigo. As a constituent business of Fortis, we will create a formidable and unique healthcare delivery institution with excellence in both diagnostics and treatment. In addition to a beneficial impact on health outcomes, we will increase our ability to support medical innovation and clinical trials."

About Fortis Healthcare (India) Limited

Fortis Healthcare (India) Limited is committed to clinical excellence and patient-centric healthcare, which is manifest in hospital design, patient services, medical programmes and the compassionate approach of medical and non-medical hospital staff. Fortis commissioned its first hospital in 2001 at Mohali, near

Chandigarh, and has expanded its operations to become a network with an over 8,000 bed capacity across 56 hospitals (includes 7 projects in pipeline). The Fortis network has a large number of international accreditations, including four JCI (Joint Commission International) and seven NABH (National Accreditation Board for Hospitals) certifications. The network's capability covers multi-speciality hospitals and super-speciality centres that provide tertiary and quaternary healthcare to patients in the major medical specialities.

About Super Religare Laboratories Ltd

SRL has an ever expanding network presently consisting of 8 reference laboratories, 7 Centres of Excellence, 181 Network Laboratories (164 pathology, 17 radiology), 15 Wellness Centres and 888 Collection Centres (including 23 abroad). During the financial year 2011, SRL served over 5.6 million customers and performed approximately 34,000 diagnostic tests per day. It provides routine (hematology and chemistry), specialized (histopathology, immunohistochemistry and cytogenetic) and esoteric tests (molecular assays and flow cytometry). It acquired Piramal Diagnostic Services Pvt Ltd (PDSPL) in August 2010 to strengthen its presence in the Radiology services and now is the largest Radiology service provider in the Country.

About the Indian Diagnostic Industry

According to a report published by ICRA Management Consultancy Services Limited (IMaCS), the Indian diagnostic Industry is expected to grow at a 28% CAGR over 2009–2015, from Rs 59.1 billion to Rs 254.4 billion. In 2009, diagnostic revenues comprised of pathology Rs 41.1 billion (70%) and radiology Rs 18 billion (30%). Within the diagnostic space, according to the report, the Pathology Laboratory revenues are expected to grow at a CAGR of 28% over 2009–2015 and Radiology Laboratories at a CAGR of 26.5% over the same period.

DISCLAIMER


This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

For further details please contact:

Ranjana Smetacek / Ruhee Dhar
Fortis Healthcare (India) Limited
9958999840 / 9818102377

Samir Kapur
Super Religare Laboratories Ltd
9582605150

Certified True Copy
For Fortis Healthcare (India) Limited


Company Secretary